Raloxifene Hydrochloride Tablet, Film Coated
Product Images NDC 0093-7290

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Raloxifene Hydrochloride (NDC 0093-7290). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

HCI stands for Human-Computer Interaction. It is an interdisciplinary field that focuses on the design and evaluation of computer systems from the perspective of the user. The goal of HCI is to make computer systems more intuitive, user-friendly, and accessible to a wider range of people. It draws on a range of disciplines, including computer science, psychology, and design, to create technologies that people can use with ease and effectiveness.*

FDA Label Image

Image 2

Total hip mean percentage change from baseline for subjects in studies A and EU who received either placebo or raloxifene hydrochloride for 24 months, as well as for subjects who received either placebo, raloxifene hydrochloride, or conjugated estrogens for 24 months in study INT (hysterectomized women). The chart displays the changes at different months after randomization.*

FDA Label Image

Image 3

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.